{"id":7138,"date":"2011-03-24T11:23:14","date_gmt":"2011-03-24T15:23:14","guid":{"rendered":"http:\/\/blogs.nejm.org\/cardioexchange\/?p=7138"},"modified":"2011-07-19T17:44:29","modified_gmt":"2011-07-19T21:44:29","slug":"study-finds-pioglitazone-prevents-progression-to-diabetes","status":"publish","type":"post","link":"https:\/\/blogs.nejm.org\/cardioexchange\/2011\/03\/24\/study-finds-pioglitazone-prevents-progression-to-diabetes\/","title":{"rendered":"Study Finds Pioglitazone Prevents Progression To Diabetes"},"content":{"rendered":"<p>Pioglitazone significantly reduces the development of type 2 diabetes  in people with impaired glucose tolerance, according to <a href=\"http:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa1010949?query=featured_home#t=abstract\">the  results of the ACT NOW study published in the <em>New England Journal  of Medicine<\/em><\/a>.<\/p>\n<p>Ralph DeFronzo and colleagues randomized 602 patients with impaired  glucose tolerance to pioglitazone or placebo. During a median followup  of\u00a0 2.4 years, diabetes developed in 16.7% of the placebo group versus 5%  in the pioglitazone group (HR for pioglitazone 0.28, CI  0.16-0.49, p&lt;0.001). The investigators calculated that 18 people  needed to be treated for one year to prevent one case of diabetes. In  addition to its beneficial effects on glucose metabolism, pioglitazone  was associated with a decrease in diastolic blood pressure, reduced CIMT  thickening, and increased HDL cholesterol. On a less positive note,  pioglitazone caused a significantly larger weight gain (3.9 kg vs 0.77  kg) and more edema than did placebo.<\/p>\n<p>The investigators acknowledged that the effect of pioglitazone on  long-term diabetic complications has not been determined.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Pioglitazone significantly reduces the development of type 2 diabetes in people with impaired glucose tolerance, according to the results of the ACT NOW study published in the New England Journal of Medicine. Ralph DeFronzo and colleagues randomized 602 patients with impaired glucose tolerance to pioglitazone or placebo. During a median followup of\u00a0 2.4 years, diabetes [&hellip;]<\/p>\n","protected":false},"author":196,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1,7],"tags":[755,415,469],"class_list":["post-7138","post","type-post","status-publish","format-standard","hentry","category-general","category-prevention","tag-glucose-tolerance","tag-pioglitazone","tag-type-2-diabetes"],"_links":{"self":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts\/7138","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/users\/196"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/comments?post=7138"}],"version-history":[{"count":0,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts\/7138\/revisions"}],"wp:attachment":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/media?parent=7138"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/categories?post=7138"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/tags?post=7138"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}